Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2015 Oct 4

PMID 26432795

Citations 77

Authors

Ursula Ehmer

Julien Sage

Affiliations

Soon will be listed here.

Abstract

The control of cell division is essential for normal development and the maintenance of cellular homeostasis. Abnormal cell proliferation is associated with multiple pathological states, including cancer. Although the Hippo/YAP signaling pathway was initially thought to control organ size and growth, increasing evidence indicates that this pathway also plays a major role in the control of proliferation independent of organ size control. In particular, accumulating evidence indicates that the Hippo/YAP signaling pathway functionally interacts with multiple other cellular pathways and serves as a central node in the regulation of cell division, especially in cancer cells. Here, recent observations are highlighted that connect Hippo/YAP signaling to transcription, the basic cell-cycle machinery, and the control of cell division. Furthermore, the oncogenic and tumor-suppressive attributes of YAP/TAZ are reviewed, which emphasizes the relevance of the Hippo pathway in cancer.

Citing Articles

Biomolecules Increase Glycolysis and Invasive Potential in Lung Adenocarcinoma.

Vega A, Shah P, Rouchka E, Clem B, Dean C, Woodrum N Cancers (Basel). 2025; 17(3).

PMID: 39941749 PMC: 11815989. DOI: 10.3390/cancers17030380.

YAP/TAZ-associated cell signaling - at the crossroads of cancer and neurodevelopmental disorders.

Ajongbolo A, Langhans S Front Cell Dev Biol. 2025; 13:1522705.

PMID: 39936032 PMC: 11810912. DOI: 10.3389/fcell.2025.1522705.

Distinct mechanisms regulate ventricular and atrial chamber wall formation.

Albu M, Affolter E, Gentile A, Xu Y, Kikhi K, Howard S Nat Commun. 2024; 15(1):8159.

PMID: 39289341 PMC: 11408654. DOI: 10.1038/s41467-024-52340-3.

Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer.

Mustafa M, Abbas K, Alam M, Habib S, Zulfareen , Hasan G Front Oncol. 2024; 14:1427802.

PMID: 39087024 PMC: 11288929. DOI: 10.3389/fonc.2024.1427802.

Mitogen signaling strength and duration can control cell cycle decisions.

Nussinov R, Zhang W, Liu Y, Jang H Sci Adv. 2024; 10(27):eadm9211.

PMID: 38968359 PMC: 11809619. DOI: 10.1126/sciadv.adm9211.

References

Zhou D, Conrad C, Xia F, Park J, Payer B, Yin Y . Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009; 16(5):425-38. PMC: 3023165. DOI: 10.1016/j.ccr.2009.09.026. View

Jung S, Kang J, Lee J, Song K, Ko J, Kim Y . PHLPP1 regulates contact inhibition by dephosphorylating Mst1 at the inhibitory site. Biochem Biophys Res Commun. 2014; 443(4):1263-9. DOI: 10.1016/j.bbrc.2013.12.129. View

Deng H, Wang W, Yu J, Zheng Y, Qing Y, Pan D . Spectrin regulates Hippo signaling by modulating cortical actomyosin activity. Elife. 2015; 4:e06567. PMC: 4412106. DOI: 10.7554/eLife.06567. View

Yimlamai D, Christodoulou C, Galli G, Yanger K, Pepe-Mooney B, Gurung B . Hippo pathway activity influences liver cell fate. Cell. 2014; 157(6):1324-1338. PMC: 4136468. DOI: 10.1016/j.cell.2014.03.060. View

Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H . Structural insights into the YAP and TEAD complex. Genes Dev. 2010; 24(3):235-40. PMC: 2811825. DOI: 10.1101/gad.1865810. View

Keshet R, Adler J, Ricardo Lax I, Shanzer M, Porat Z, Reuven N . c-Abl antagonizes the YAP oncogenic function. Cell Death Differ. 2014; 22(6):935-45. PMC: 4423178. DOI: 10.1038/cdd.2014.182. View

Sarikaya D, Extavour C . The Hippo pathway regulates homeostatic growth of stem cell niche precursors in the Drosophila ovary. PLoS Genet. 2015; 11(2):e1004962. PMC: 4333732. DOI: 10.1371/journal.pgen.1004962. View

Calo E, Quintero-Estades J, Danielian P, Nedelcu S, Berman S, Lees J . Rb regulates fate choice and lineage commitment in vivo. Nature. 2010; 466(7310):1110-4. PMC: 2933655. DOI: 10.1038/nature09264. View

Ota M, Sasaki H . Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development. 2008; 135(24):4059-69. DOI: 10.1242/dev.027151. View

10.

Feng X, Degese M, Iglesias-Bartolome R, Vaque J, Molinolo A, Rodrigues M . Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014; 25(6):831-45. PMC: 4074519. DOI: 10.1016/j.ccr.2014.04.016. View

11.

Kim M, Kim M, Lee M, Kim C, Lim D . The MST1/2-SAV1 complex of the Hippo pathway promotes ciliogenesis. Nat Commun. 2014; 5:5370. DOI: 10.1038/ncomms6370. View

12.

Zhang N, Bai H, David K, Dong J, Zheng Y, Cai J . The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell. 2010; 19(1):27-38. PMC: 2925178. DOI: 10.1016/j.devcel.2010.06.015. View

13.

Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V . Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 2013; 134(1):123-132. PMC: 3938155. DOI: 10.1038/jid.2013.319. View

14.

Camargo F, Gokhale S, Johnnidis J, Fu D, Bell G, Jaenisch R . YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007; 17(23):2054-60. DOI: 10.1016/j.cub.2007.10.039. View

15.

Reddy B, Irvine K . Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev Cell. 2013; 24(5):459-71. PMC: 3624988. DOI: 10.1016/j.devcel.2013.01.020. View

16.

Urtasun R, Latasa M, Demartis M, Balzani S, Goni S, Garcia-Irigoyen O . Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology. 2011; 54(6):2149-58. DOI: 10.1002/hep.24587. View

17.

Grijalva J, Huizenga M, Mueller K, Rodriguez S, Brazzo J, Camargo F . Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. Am J Physiol Gastrointest Liver Physiol. 2014; 307(2):G196-204. DOI: 10.1152/ajpgi.00077.2014. View

18.

Huang J, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A . YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. 2012; 32(17):2220-9. PMC: 3443515. DOI: 10.1038/onc.2012.231. View

19.

Shen Z, Stanger B . YAP regulates S-phase entry in endothelial cells. PLoS One. 2015; 10(1):e0117522. PMC: 4312014. DOI: 10.1371/journal.pone.0117522. View

20.

Morin-Kensicki E, Boone B, Howell M, Stonebraker J, Teed J, Alb J . Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol. 2005; 26(1):77-87. PMC: 1317614. DOI: 10.1128/MCB.26.1.77-87.2006. View